Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy
- 12 July 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (10) , 980-989
Abstract
Aims: To evaluate the effect of testosterone replacement therapy (TRT) on body composition, insulin sensitivity, oxidative metabolism and glycaemic control in aging men with lowered bioavailable testosterone (BioT) levels and type 2 diabetes mellitus (T2D) controlled on metformin monotherapy. Materials and methods: We conducted a randomized, double‐blind, placebo‐controlled study in 39 men aged 50‐70 years with BioT levels <7.3 nmol/L and T2D treated with metformin monotherapy. Patients were randomized to testosterone gel (TRT, n = 20) or placebo (n = 19) for 24 weeks. Lean body mass (LBM), total and regional fat mass were measured using whole‐body dual‐energy X‐ray absorptiometry scans. Whole‐body peripheral insulin sensitivity, endogenous glucose production (EGP) and substrate oxidation were assessed by euglycaemic‐hyperinsulinaemic clamp with glucose tracer and combined with indirect calorimetry. Coefficients (β) represent the placebo‐controlled mean effect of intervention. Results: LBM (β = 1.9 kg, p = 0.001) increased after TRT, while total fat mass (β = −1.3 kg, p = 0.009), fat mass trunk (β = −0.7 kg, p = 0.043), fat mass legs (β = −0.7 kg, p = 0.025), fat mass arms (β = −0.3 kg, p = 0.001), and HDL cholesterol (β = −0.11 mmol/L, p = 0.009) decreased after TRT compared with placebo. Insulin‐stimulated glucose disposal rates did not change in response to TRT compared with placebo (p = 0.18). Moreover, glycated haemoglobin, and basal and insulin‐stimulated rates of EGP, lipid‐ and glucose‐oxidation were unaltered after TRT. Conclusion: TRT in aging men with lowered BioT levels and T2D controlled on metformin monotherapy improved body composition; however, glycaemic control, peripheral insulin sensitivity, EGP and substrate metabolism were unchanged.Keywords
Funding Information
- Odense Universitetshospital
This publication has 42 references indexed in Scilit:
- Gonadal Steroids and Body Composition, Strength, and Sexual Function in MenNew England Journal of Medicine, 2013
- Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trialsBMC Medicine, 2013
- Comment on: Jones et al. Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study). Diabetes Care 2011;34:828–837Diabetes Care, 2011
- Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)Diabetes Care, 2011
- Testosterone therapy increased muscle mass and lipid oxidation in aging menAGE, 2011
- Adverse Events Associated with Testosterone AdministrationNew England Journal of Medicine, 2010
- Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2010
- Testosterone Concentrations in Diabetic and Nondiabetic Obese MenDiabetes Care, 2010
- Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older MenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Quantitation of Muscle Glycogen Synthesis in Normal Subjects and Subjects with Non-Insulin-Dependent Diabetes by13C Nuclear Magnetic Resonance SpectroscopyNew England Journal of Medicine, 1990